A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care.

Presenters:

Eytan M. Stein, MD
Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Eunice S. Wang, MD
Chief, Leukemia Service
Professor of Oncology
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Link to full program: 
https://bit.ly/4f4an0O

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.